期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他克莫司用于肾移植临床治疗的进展 被引量：5

Update of tacrolimus in clinical kidney transplantation
原文传递
导出
摘要 钙调神经磷酸酶抑制剂他克莫司已成为临床肾移植的首选用药,但相关肾毒性、糖代谢障碍等不良反应影响了临床肾移植的远期疗效,本文综述近年临床西罗莫司、依维莫司,以及选择性蛋白激酶C抑制剂(sotrastaurin)、Janus激酶-3抑制剂(CP-690550)、CTLA-4融合蛋白(belatacept)等新型药物用于降低他克莫司用量或替代他克莫司等研究进展,为他克莫司的临床个体化用药提供参考。 The calcineurin inhibitor--tacrolimus has become the first-line immunosuppressant in clinical kidney transplantation. However, the adverse reactions of tacrolimus such as nephrotoxicity and metabolism disorders affect longterm outcome of kidney transplantation. This review focuses the updates of tacrolimus in kidney transplantation to minimize or avoid tacrolimus in new immunosuppressive regimens which involved sirolimus, everolimus, protein kinase C inhibitor （sotrastaurin）, Janus kinase-3 inhibitor （CP-690550） or CTLA-4 fusion protein （belatacept）.
作者 刘龙山 王长希
机构地区 中山大学附属第一医院器官移植中心
出处 《世界临床药物》 CAS 2014年第3期134-140,共7页 World Clinical Drug
关键词 他克莫司 肾移植 药物基因组学 合理用药 tacrolimus kidney transplantation pharmacogenetics rational drug use
分类号 R979.5 [医药卫生—药品] R617 [医药卫生—外科学]
  • 相关文献

参考文献54

  • 1Wallemacq PE, Reding R. FKS06 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects [J]. Clin Chem, 1993,39 (11 Pt 1) : 2219-2228.
  • 2Perico N, Remuzzi G. Prevention of transplant rejection current treatment guidelines and future developments [J] Drugs, 1997, 54(4): 533-570.
  • 3戴宇平,刘雅峰,王长希,等.免疫抑制剂的药物代谢动力学//郑克立.临床肾移植学[M].北京:科学技术文献出版社,2006:135-163.
  • 4Anon. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients [J]. Am J Transplant, 2009, 9 (Suppl 3): S1-S155.
  • 5Anon. OPTN/SRTR 2011 Annual Data Report. kindney E2013-05-20] http://srtr.transplant.hrsa.gov/annual_reports/ 2011/Default.aspx.
  • 6Elens L, Hesselink DA, van Schaik RH, et al. Pharma- cogenetics in kidney transplantation: recent updates and potential clinical applications[J]. Mol Diagn Ther, 2012, 16(6): 331-345.
  • 7Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J]. Nat Genet, 2001, 27 (4) : 383-391.
  • 8Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients[J]. Transplantation, 2004, 78 (8) : 1182-1187.
  • 9Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB 1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study [J]. Am J Transplant, 2006,6 (11) : 2706-2713.
  • 10Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients . Pharmacogenetics, 2004, 14 (3): 147-154.

二级参考文献25

  • 1[1]Paterson DL,Singh N.Interactions between tacrolimus and antimicrobial agents[J].Clin Infect Dis,1997,25(6):1430.
  • 2[2]Padhi ID,Long P,Basha M,et al.Interaction between tacrolimus and erythromycin[J].Ther Drug Monit,1997,19(1):120.
  • 3[3]Hebert MF,Fisher RM,Marsh CL,et al.Effect of rifampin on tacrolimus pharmacokinetics in healthy volunteers[J].J Clin Pharmacol,1999,39(1):91.
  • 4[4]Schulman SL,Shaw LM,Jabs K,et al.Interaction between tacrolimus and chloramphenicol in a renal transplant recipient[J].Transplantation,1998,65(10):1397.
  • 5[5]Albengres E,Lelouet H,Tillement JP,et al.Systemic antifungal agents.Drug interaction of clinical significance[J].Transplantation,1991,52(6):1086.
  • 6[6]Mieles,L R. Venkataramanan,I. Yokoyama,et al.Interaction between fk506 and clotrimazole in a liver transplant recipient[J].Transplantatioin,1991,52(6):1086.
  • 7[7]Floren LC,Bekersky I,Benet LZ,et al.Tacrolimus oral bioavailbility doubles with coadministration of ketoconazole[J].Clin Pharmacol Ther,1997,62(10):41.
  • 8[8]Seifeldin RA,Marcos-Alvarez A,Gordon FD,et al.Nifedipine interaction with tacrolimus in liver transplant recipients[J].Ann Pharmacother,1997,31(5):571.
  • 9[9]Stephan K,Andrea M,Emile G,et al.Serious interaction between mibefradil and tacrolimus [J].Transplantation,1998,66(8):1113.
  • 10[10]Patrick A T,Coleman A M.Tacrolimus phenytoin interaction[J].The Annals of Pharmacotherapy,1996,30:544.

共引文献27

同被引文献114

引证文献5

二级引证文献17

世界临床药物
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部